IL2 and breast cancer: CD4 + T-cell reduction diminishes pro-inflammatory cytokine levels, including interleukin 2 (IL-2) and tumor necrosis factor α (TNF-α) as observed in many tumors, including BC [37, 43, 72, 98, 123].